GOSS
NASDAQ HealthcareGossamer Bio, Inc. - Common Stock
Biotechnology
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
�� 市场数据
| 价格 | $0.20 |
|---|---|
| 成交量 | 11,491,307 |
| 市值 | 46.99M |
| 贝塔系数 | 2.150 |
| RSI（14日） | 26.0 超卖 |
| 200日均线 | $1.89 |
| 50日均线 | $0.33 |
| 52周最高 | $3.87 |
| 52周最低 | $0.16 |
| Forward P/E | -1.83 |
| Price / Book | -0.29 |
🎯 投资策略评分
GOSS 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🔪 Falling Knife (99/100) — 此策略 逆向投资（超卖 + 低于移动均线）.
评分最低的策略： 🐋 Institutional Whale (1/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 GOSS in your text
粘贴任何文章、记录或帖子 — 工具将提取 GOSS 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-06-02.